Molina Healthcare stock rating held at Neutral by Cantor Fitzgerald

Molina Healthcare (MOH) saw a significant improvement in its 2026 Medicare Advantage Stars ratings, rising to 5% from 0%, a critical factor influencing 2027 bonus payments and reimbursement rates, leading Cantor Fitzgerald to maintain a Neutral rating. Conversely, Humana (HUM) experienced slight declines in its Stars ratings, creating headwinds despite announcing stable 2026 Medicare Advantage benefits; however, analysts like Wolfe Research and Raymond James have raised or reiterated Outperform ratings with price targets up to $340, while Cantor Fitzgerald remains Neutral. This divergence highlights the crucial impact of Stars ratings on financial performance and competitive dynamics within the healthcare insurance industry.

Analysis

Molina Healthcare (MOH) has demonstrated significant operational improvement, with its 2026 Stars ratings increasing to 5% from 0%, particularly for its Duals-heavy population. This enhancement is a critical performance metric, directly influencing 2027 bonus payments and reimbursement rates, positioning MOH favorably among peers like UnitedHealth Group and Elevance Health who also saw positive changes. Cantor Fitzgerald maintains a Neutral rating on MOH with a $210 price target, acknowledging this progress.

Conversely, competitor Humana (HUM) experienced slight declines in its 2026 Stars ratings, facing a $281 million headwind and changes in Indiana Medicaid enrollment requirements. Despite these challenges, Humana announced stable 2026 Medicare Advantage benefits for over 80% of its members, and analysts like Wolfe Research and Raymond James have reiterated or raised Outperform ratings, with price targets up to $340. Cantor Fitzgerald, however, maintains a Neutral rating with a $290 price target for HUM.

The divergence in Stars rating performance among major healthcare insurers underscores the metric's crucial impact on financial health and competitive dynamics. While MOH's improvement signals potential future revenue stability, Humana's situation presents a mixed picture where analyst confidence in strategic adjustments contrasts with immediate rating pressures. Investors should note the upcoming Medicare Annual Election Period from October 15 to December 7 as a key period for Humana's plan selections.

Key Decisions for Investors

• Monitor upcoming 2026 Medicare Advantage Star ratings announcements and their potential impact on bonus payments and reimbursement rates for healthcare insurers.
• Evaluate Molina Healthcare's improved Stars ratings as a potential positive catalyst for 2027 financial performance, despite its current Neutral rating from Cantor Fitzgerald.
• Consider the divergence in analyst ratings and Star rating performance for Humana, weighing the long-term strategic moves and stable benefits against immediate headwinds and rating declines.